On August 21st, eyebright medical technology (beijing) co., ltd. (688050.SH) released its semi-annual report for 2024, achieving revenue of 0.686 billion yuan, a year-on-year increase of 68.54%; net income attributable to the shareholders of the listed company was 0.208 billion yuan, a year-on-year increase of 27.49%; net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 0.199 billion yuan, a year-on-year increase of 29.95%; basic earnings per share were 1.1 yuan.
The net income attributable to the shareholders of the listed company increased by 27.49% year-on-year during this reporting period. Net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses increased by 29.95% year-on-year. The growth in revenue drove the overall gross margin growth, but the overall gross margin of the company decreased due to the impact of lower prices after the centralized procurement of artificial crystalline lenses, and the expansion of the proportion of revenue from the vision health business mainly focused on contact lens products. In addition, the contact lens business is in a phase of capacity expansion, with various costs being relatively high, and the profit margin has not yet reached a stable level, affecting the overall net income growth rate of the company.
